{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:16Z","timestamp":1791876916015,"version":"4.3.4"},"reference-count":90,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>B\u2010cell maturation antigen (BCMA)\u2010directed chimeric antigen receptor (CAR) T\u2010cell therapies have revolutionized the approach and management of relapsed\/refractory multiple myeloma (RRMM), and as of 2025, idecabtagene vicleucel (ide\u2010cel) and ciltacabtagene autoleucel (cilta\u2010cel) are the only BCMA\u2010targeted CAR T\u2010cell therapies approved by the FDA. Exceptional responses were demonstrated for heavily pretreated patients in the KarMMa\u20101 trial, reporting a 73% overall response rate (ORR) and 98% in the CARTITUDE\u20101 trial. Furthermore, both therapies show a significant improvement in progression\u2010free survival (PFS) compared to standard regimens when administered in earlier lines. Current real\u2010world evidence confirms their effectiveness and manageable safety in a more diverse patient population, including those who would have been ineligible for clinical trials. Key toxicities include cytokine release syndrome (CRS) and neurotoxicity, with emerging concerns regarding delayed neurotoxicities, second primary malignancies, and IEC\u2010enterocolitis. This review provides a detailed analysis of recent clinical trial data, the reported outcomes of real\u2010world published evidence, and the changing role of these therapies within the myeloma treatment paradigm, including challenges, gaps in knowledge, potential barriers to accessibility, and future directions aimed at optimizing the efficacy and safety of CAR T\u2010cell therapy for MM patients.<\/jats:p>","DOI":"10.1111\/ejh.70025","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:19:57Z","timestamp":1757513997000},"page":"533-546","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real\u2010World Evidence"],"prefix":"10.1111","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9711-7473","authenticated-orcid":false,"given":"Hector Garcia","family":"Pleitez","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Texas Tech University Health Sciences Center  Lubbock Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakditad","family":"Saowapa","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology and Blood &amp; Marrow Transplantation University of Iowa  Iowa City Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Ortiz","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Texas Tech University Health Sciences Center  Lubbock Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanakarn","family":"Kanitthamniyom","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Texas Tech University Health Sciences Center  Lubbock Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Olavarria","family":"Bernal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Texas Tech University Health Sciences Center  Lubbock Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukman","family":"Tijani","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology Texas Tech University Health Sciences Center  Lubbock Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)61029-X"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62885-0"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1948032"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0199"},{"key":"e_1_2_13_14_1","first-page":"404991","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA\u2010Based Immunotherapy","volume":"9","author":"Cho S. F.","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102003\u201006\u20102043"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141152"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0337-y"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2018.1448269"},{"key":"e_1_2_13_19_1","volume-title":"Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma","author":"Study Details","year":"2025"},{"key":"e_1_2_13_20_1","volume-title":"A Study of JNJ\u201068284528, a Chimeric Antigen Receptor T Cell (CAR\u2010T) Therapy Directed Against B\u2010Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma","author":"Study Details","year":"2025"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155192"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/980250"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2276676"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00750-2"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991092"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010206422"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010206347"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010201288"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010201194"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205226"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010212331"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010203007"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010205126"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_2_13_39_1","unstructured":"ABECMA (Idecabtagene Vicleucel) \u201cFDA \u201d(2025) https:\/\/www.fda.gov\/vaccines\u2010blood\u2010biologics\/abecma\u2010idecabtagene\u2010vicleucel."},{"key":"e_1_2_13_40_1","unstructured":"CARVYKTI \u201cFDA \u201d(2025) https:\/\/www.fda.gov\/vaccines\u2010blood\u2010biologics\/cellular\u2010gene\u2010therapy\u2010products\/carvykti."},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon\u20102021\u20101090"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00094-9"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010199771"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.242"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2476382"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899\u2010021\u201000635\u20103"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.01.012"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282896"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.022"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000846344.56300.e1"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010165613"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01097"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01049-z"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03538-6"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8035"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15556"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00690"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201533"},{"key":"e_1_2_13_62_1","unstructured":"Cancer Institute N \u201cCommon Terminology Criteria for Adverse Events (CTCAE) Version 4.0 \u201d(2009) http:\/\/www.meddramsso.com."},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201005\u2010552729"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02496-0"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181762"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013540"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19505"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526"},{"key":"e_1_2_13_71_1","unstructured":"S.Sidana K. K.Patel L. C.Peres et\u00a0al. \u201cSafety and Efficacy of Standard\u2010of\u2010Care Ciltacabtagene Autoleucel for Relapsed\/Refractory Multiple Myeloma \u201dhttp:\/\/ashpublications.org\/blood\/article\u2010pdf\/145\/1\/85\/2349639\/blood_bld\u20102024\u2010025945\u2010main.pdf."},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27425"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17717"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014345"},{"key":"e_1_2_13_75_1","doi-asserted-by":"crossref","unstructured":"M.Elsallab M.Ellithi M. A.Lunning et\u00a0al. \u201cSecond Primary Malignancies After Commercial CAR T\u2010Cell Therapy: Analysis of the FDA Adverse Events Reporting System \u201dhttp:\/\/ashpublications.org\/blood\/article\u2010pdf\/143\/20\/2099\/2225489\/blood_bld\u20102024\u2010024166\u2010main.pdf.","DOI":"10.1182\/blood.2024024166"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5412"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03478-6"},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401530"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01167-8"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010179050"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190583"},{"key":"e_1_2_13_82_1","unstructured":"CMS \u201cMedicare Coverage Related to Investigational Device Exemption (IDE) Studies \u201dhttps:\/\/www.cms.gov\/medicare\/coverage\/investigational\u2010device\u2010exemption\u2010ide\u2010studies."},{"key":"e_1_2_13_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00315"},{"key":"e_1_2_13_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19302"},{"key":"e_1_2_13_85_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201000760"},{"key":"e_1_2_13_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8053"},{"key":"e_1_2_13_87_1","volume-title":"Study Details | A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)","year":"2025"},{"key":"e_1_2_13_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010178882"},{"key":"e_1_2_13_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010146210"},{"key":"e_1_2_13_90_1","volume-title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","author":"Study Details","year":"2025"},{"key":"e_1_2_13_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7563"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:50:55Z","timestamp":1762221055000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/ejh.70025"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70025","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"2025-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}